**Breast:**

**Adjuvant**

_AFT-05/BIG 14-03 PALLAS-_ A Randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER-2) negative early breast cancer.  

_NRG BR003-_ A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.

**Metastatic:**

_ACCRU RU011201I-_ A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.  

_ECOC-A003-_ A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer.

**Cancer Control**

None

**GYN Studies:**

**Ovary**

_GOG 0225-_ Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?  

_NRG GY003-_ Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

**Colon:**

**Adjuvant**

None

**Registry**

_NSABP MPR-1-_ Patient Registry and Biospecimen Profiling Registry for Patients with Metastatic Colorectal Cancer who have had tumor resection

**Pancreatic:**

**Metastatic**

_SWOG S1313-_ A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.

**Prostate:**

**Metastatic**

_ALLIANCE A031201-_ Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzulutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer.
Lung:

**Adjuvant:**
- **Alliance A151216**- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- **Alliance A081105**- Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
- **ECOG-ACRIN E4512**- A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- **ECOG-ACRIN EA5142**- A Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

**NSCL Metastatic:**
- **Amgen 20070782**- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500mcg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy
- **BMS CheckMate 370**- A Master Protocol of Phase I/II Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-Line Treatment Alone or in Combination with Standard of Care Therapies.
- **SWOG S1400**- Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-Map)
  - **S1400B**: PK+, GDC-0032
  - **S1400C**: Cell cycle gene alteration +, palbociclib
  - **S1400D**: FGFR+, AZD4547
  - **S1400I**: Non-Match – Nivolumab/Ipilimumab vs Nivolumab

**Lymphoma: None**

**Multiple Myeloma:**

**Treatment:**
- **Maia 54767414MMY3008**- A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

**Registry:**
- **UNC LCCC 0916**- UNC Carolina Senior Registry